Rethinking the safety and efficacy assessment of (Hybrid) Closed Loop systems: Should we promote the need for a minimum of exercise data within the regulatory approval?
- PMID: 38332559
- DOI: 10.1111/dme.15305
Rethinking the safety and efficacy assessment of (Hybrid) Closed Loop systems: Should we promote the need for a minimum of exercise data within the regulatory approval?
References
REFERENCES
-
- Pemberton JS, Wilmot EG, Barnard-Kelly K, et al. CGM accuracy: contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): a narrative review. Diabetes Obes Metab. 2023;25(4):916-939. doi:10.1111/DOM.14962
-
- Klonoff DC, James Petisce FR, Bailey TS, et al. Performance Metrics for Continuous Interstitial Glucose Monitoring Suggested Citation. Published online 2020. Accessed February 3, 2024 www.clsi.org
-
- CFR - Code of Federal Regulations Title 21. Accessed February 3, 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?f...
-
- Alva S, Brazg R, Castorino K, Kipnes M, Liljenquist DR, Liu H. Accuracy of the third generation of a 14-day continuous glucose monitoring system. Diabetes Ther. 2023;14(4):767-776. doi:10.1007/S13300-023-01385-6
-
- Freckmann G, Eichenlaub M, Waldenmaier D, et al. Clinical performance evaluation of continuous glucose monitoring systems: a scoping review and recommendations for reporting. J Diabetes Sci Technol. 2023;17(6):1506-1526. doi:10.1177/19322968231190941
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical